Femasys (NASDAQ:FEMY – Get Free Report) and Outset Medical (NASDAQ:OM – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.
Profitability
This table compares Femasys and Outset Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Femasys | -534.36% | -225.97% | -74.68% |
| Outset Medical | -63.06% | -61.67% | -28.25% |
Valuation and Earnings
This table compares Femasys and Outset Medical”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Femasys | $2.29 million | 7.32 | -$18.63 million | ($3.53) | -0.57 |
| Outset Medical | $119.48 million | 0.64 | -$81.65 million | ($4.09) | -0.99 |
Femasys has higher earnings, but lower revenue than Outset Medical. Outset Medical is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations for Femasys and Outset Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Femasys | 1 | 0 | 3 | 0 | 2.50 |
| Outset Medical | 1 | 1 | 3 | 0 | 2.40 |
Femasys presently has a consensus price target of $50.00, suggesting a potential upside of 2,400.00%. Outset Medical has a consensus price target of $10.00, suggesting a potential upside of 146.91%. Given Femasys’ stronger consensus rating and higher probable upside, equities analysts plainly believe Femasys is more favorable than Outset Medical.
Institutional & Insider Ownership
65.3% of Femasys shares are held by institutional investors. 7.7% of Femasys shares are held by company insiders. Comparatively, 2.5% of Outset Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Femasys has a beta of -2.16, suggesting that its stock price is 316% less volatile than the S&P 500. Comparatively, Outset Medical has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500.
Summary
Femasys beats Outset Medical on 8 of the 13 factors compared between the two stocks.
About Femasys
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
About Outset Medical
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.
